Trials / No Longer Available
No Longer AvailableNCT01659515
Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- U.S. Army Medical Research and Development Command · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Arbekacin for the use of infection caused by multidrug-resistant organisms
Detailed description
The primary purpose of this protocol is to make arbekacin available for treatment of patients with infections caused by multidrug-resistant organisms when treatment with other antibiotics cannot be used due to unavailability, intolerance, contraindications, or treatment non-response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Arbekacin Sulfate | Intravenous arbekacin in a total daily dose of 5-7 mg/kg |
Timeline
- First posted
- 2012-08-07
- Last updated
- 2020-01-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01659515. Inclusion in this directory is not an endorsement.